01 — At a Glance
The Oncology Rocket That Just Had a Mid-Flight Crisis
- 52-Week High / Low₹10,691 / ₹6,502
- Current Market Price₹8,800
- Q3 FY26 Revenue₹612 Cr
- Q3 FY26 PAT₹33 Cr
- Q3 FY26 EPS₹13.04
- Book Value₹320
- Price to Book27.5x
- Dividend Yield0.37%
- Debt / Equity0.04x
- Q3 Profit Decline YoY-42.3%
Auditor’s Confession: AstraZeneca India closed Q3 FY26 with ₹612 crore revenue (+38.9% YoY), but here’s the plot twist — PAT collapsed -42.3% YoY to ₹33 crore. The stock price fell -3.8% in 3 months. EPS at ₹13.04 (annualised ~₹52.16) means the P/E of 106x is not a typo — it’s a feature, not a bug. Welcome to the pharmaceutical volatility circus where growth is spectacular, losses are catastrophic, and valuations live in parallel universes.
02 — Introduction
The British Pharma That Made India Its Oncology Playground
AstraZeneca Pharma India is 75% owned by AstraZeneca Pharmaceuticals AB — one of the world’s top 5 pharmaceutical companies, headquartered in Sweden, with a clinical presence in over 160 countries. You know them for the Oxford-AstraZeneca COVID vaccine. The one that gave millions of Indians a 12-week wait between doses. We remember.
But let’s talk about India specifically. This subsidiary has transformed itself from a mid-tier generics company into India’s third-fastest-growing MNC pharmaceutical player. In just 3 years, it climbed 12 positions in the Oncology therapeutic area and is now ranked third overall. That’s not growth. That’s a hostile takeover of a market segment through science and billions of R&D money.
The company’s portfolio is split across Cardiovascular-Renal-Metabolics (CVRM), Oncology, Respiratory, and Immunology. But here’s the thing — Oncology went from 47% of revenue in FY22 to 56% in FY23. The company is leaning harder into cancer treatments. Which means it’s leaning harder into high-ticket medicines, complex manufacturing, regulatory nightmares, and the kind of volatility that makes your profit swing ±40% between quarters.
Q3 FY26 delivered the highest-ever quarterly revenue of ₹612 crore. But PAT crashed 42.3% YoY. The stock went down. Analysts are confused. We’re here to explain what actually happened — and whether you should care.
Context Note: AstraZeneca’s latest CDSCO approvals in Q3 FY26 include Imfinzi (durvalumab) for endometrial cancer, Datverzo (datopotamab deruxtecan) for HR+/HER2- metastatic breast cancer, and Enhertu for additional HER2+ indications. Each approval is a potential ₹50–200 crore revenue driver. But manufacturing, stock buildup, and GST payments happen upfront. Revenue recognition follows a lag. That’s why profits swing wildly while sales grow linearly.
03 — Business Model: Pills, Patents, and Prayers
How AstraZeneca Makes Money in India (Spoiler: Slowly and Expensively)
The business model is stupidly simple: invent expensive drugs globally, get patent exclusivity in India for 7–20 years, charge premium prices to private hospitals, and repeat. The company does NOT manufacture most of its key drugs in India. It imports finished goods, repackages, and sells through 350+ hospital relationships, 1.2 lakh retail outlets, and a growing digital pharmacy ecosystem.
Oncology is where the margins are. A single-vial Imfinzi injection costs ₹3–5 lakh per dose. A patient might need 6–12 doses. Do the math. One successfully treated patient = ₹30–60 lakh revenue. But here’s the catch — manufacturing is outsourced, supply chains are Byzantine, regulatory approvals take 18–36 months, and post-launch it takes 2–3 quarters to build stock and patient awareness.
The company surrendered its manufacturing licence in September 2025 (it was valid till Dec 2027) and is exiting its manufacturing site entirely. Translation: it’s going full-import model. This reduces capex, simplifies operations, but increases dependency on parent company AstraZeneca for supply. It also means higher variable costs and tighter margins.
Oncology56%of Revenue
Cardiovascular27%of Revenue
Diabetes14%of Revenue
Respiratory4%of Revenue
Manufacturing Reality Check: By exiting manufacturing, AstraZeneca saves ₹20–30 crore in annual capex and operating costs. But it also loses 5–8% gross margin. For a company with ₹2,177 crore TTM revenue and ₹201 crore PAT, that’s ₹10–17 crore annual impact. The company is choosing volume over margin — a strategic pivot toward smaller pack sizes, retail penetration, and market share over profitability. Classic growth-at-cost-of-earnings playbook.
💬 Does a pharma company that keeps asking for regulatory approvals but can’t maintain manufacturing consistency sound like a long-term winner or a funding-dependent startup? Your thoughts?
04 — Financials Overview
Q3 FY26: The Growth Paradox
Result type: Quarterly Results | Q3 FY26 EPS: ₹13.04 | Annualised EPS (Q3×4): ₹52.16 | TTM EPS: ₹80.36
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 612 | 440 | 559 | +38.9% | +9.5% |
| Operating Profit | 45 | 77 | 75 | -41.6% | -40.0% |
| OPM % | 7.4% | 17.5% | 13.4% | -1010 bps | -600 bps |
| PAT | 33 | 31 | 54 | -42.3% | -38.9% |
| EPS (₹) | 13.04 | 12.34 | 21.69 | +5.7% | -39.9% |
⚠️ Margin Collapse Alert: Revenue is up 38.9% YoY, but operating profit is down 41.6%. Operating margin cratered from 17.5% to 7.4% — a 1010 basis point decline. This isn’t normal pharmaceutical business. This is what happens when you: (a) launch multiple new drugs simultaneously (high initial costs, low initial volume), (b) build inventory ahead of regulatory approvals, (c) reset manufacturing and supply chains, and (d) give away inventory to build brand awareness in oncology hospital channels. The company is investing aggressively in growth. Revenue shows it. Profitability does not.
05 — Valuation: The Cosmic Stretch
Is 106x P/E a Bargain or a Bail Out?
Join 10,000+ investors who read this every week.
